Sensei Biotherapeutics Inc. Common Stock (SNSE)

FairStock Score: 58/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach a clinical-stage biotech as a speculation, not a Graham-style bargain. Sensei has 29 employees, a $42.6M market cap, and a $25.96 close on 2026-07-17. It is developing PIKTOR, Solnerstotug, SNS-102, and SNS-1, but it has no revenue growth figure to judge and no multi-year filed record; FairStock's Lynch category is none because only 0 years of filed results exist and three are needed. The current economics are poor: FairStock shows a P/E of -1.55, P/B of 1.76, ROE of -74.01%, ROCE of -95.24%, and trailing free cash flow of -$33.9M, a FCF yield of -79.5% of market cap. That is a lot of cash consumed relative to the company's size. The balance sheet is the one clear positive: D/E is just 0.08. Still, Piotroski 2/9 and Altman -0.77 point to financial weakness and distress risk. Beta of -0.18 and a 52-week range of $7.45 to $36.93 show erratic pricing rather than stable value. Growth depends entirely on clinical outcomes; the pipeline may be valuable if trials succeed, but there is no durable moat yet because there are no approved products, sales, or profits. At 1.76 times book, the market is paying more than accounting net assets for a business burning cash. FairStock Score 58/100 leaves it middle-of-the-road, not a compelling value. I would need evidence of trial progress, controlled cash burn, and eventual revenue before calling it a sound investment.

In plain English: Sensei Biotherapeutics is a very small clinical-stage cancer drug company with 29 employees and no meaningful product sales yet. It is losing a lot of money and burning cash, and its financial strength scores are weak, so the business looks fragile. At the 2026-07-17 close of $25.96, the price looks expensive against its accounting net assets and cash burn, though it carries very little debt.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-07-17 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer